Eli Lilly and Co. and Dicerna Pharmaceuticals Inc.'s licensing and research collaboration on RNA interference therapies closed after receiving U.S. antitrust clearance.
RNA interference, or RNAi, is a biologic process in which certain double-stranded RNA molecules hinder the expression of disease-causing genes.
The collaboration has been cleared under the Hart-Scott-Rodino Act, which means the deal has received antitrust clearance.
Indianapolis-based Eli Lilly and Dicerna previously agreed to use the latter's GalXC RNAi platform to develop new drug targets in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies plan to collaborate on over 10 targets.
The deal involves Lilly paying Dicerna $100 million up front and making an equity investment of $100 million in the Cambridge, Mass.-based company at a premium.